FONR vs SRPT · P/E 19, rev $104.4M vs rev $1.13B
Fonar Corporation (FONR) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Fonar Corporation (FONR) is a diagnostics & research company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported FONR revenue for 2025-06-30 was $104.4M. Net income was $8.3M. Revenue was up 1.4% from 2024-06-30 to 2025-06-30. FONR currently screens at market cap $120.2M and trailing P/E 19.1.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
FONR currently screens at market cap $120.2M and trailing P/E 19.1. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the FONR and SRPT stock pages for the full models.
Not investment advice.